Market Place
Sourcing Support
Moleculin`s Annamycin Overcomes Resistance to Venetoclax in AML
18 Nov 2024 //
PR NEWSWIRE
Moleculin Advances MIRACLE Trial Data Readout to H2 2025
14 Nov 2024 //
PR NEWSWIRE
Moleculin Receives IRB Approval for MIRACLE Phase 3 AML Trial
12 Nov 2024 //
PR NEWSWIRE
Moleculin Reports Q3 2024 Financial Results & Corporate Update
11 Nov 2024 //
PR NEWSWIRE
Moleculin to Report Q3 2024 Financial Results on Nov 8
05 Nov 2024 //
PR NEWSWIRE
Moleculin Appoints Expert to Advisory Board for Pancreatic Cancer
04 Nov 2024 //
PR NEWSWIRE
Transcript from Moleculin`s Virtual Acute Myeloid Leukemia KOL Event
17 Oct 2024 //
PR NEWSWIRE
Moleculin Hosts Virtual AML KOL Event On October 14, 2024
07 Oct 2024 //
PR NEWSWIRE
Moleculin to Present at Two Upcoming Investor Conferences
04 Oct 2024 //
PR NEWSWIRE
Moleculin Reports Positive Annamycin Data In Sarcoma Models
23 Sep 2024 //
PR NEWSWIRE
Moleculin Participates in Virtual Investor What this Means" Segment"""
16 Sep 2024 //
PR NEWSWIRE
Moleculin Treats First Patients In Phase 2 STAT3 Inhibitor GBM Trial
09 Sep 2024 //
PR NEWSWIRE
Moleculin to Present at H.C. Wainwright 26th Annual Global Investment Conference
03 Sep 2024 //
PR NEWSWIRE
Moleculin To Present At LIVE! Webull Healthcare Investment Webinar
26 Aug 2024 //
PR NEWSWIRE
Moleculin Announces Closing of up to $16.5 Million Public Offering
19 Aug 2024 //
PR NEWSWIRE
Moleculin Announces Pricing of up to $16.5 Million Public Offering
16 Aug 2024 //
PR NEWSWIRE
Moleculin Reports Q2 2024 Results And Provides Corporate Update
14 Aug 2024 //
PR NEWSWIRE
Moleculin To Host Webcast On MIRACLE Phase 3 Trial Plans
05 Aug 2024 //
PR NEWSWIRE
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
01 Aug 2024 //
PR NEWSWIRE
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
10 Jul 2024 //
PR NEWSWIRE
Moleculin Announces Additional Positive AML Trial Data
14 Jun 2024 //
PR NEWSWIRE
Moleculin to Present at the Virtual Investor Pitch Conference
12 Jun 2024 //
PR NEWSWIRE
Moleculin Begins NIH-Funded Glioblastoma Phase 2 For STAT3 Inhibitor NU 21C06
15 May 2024 //
PR NEWSWIRE
Moleculin Reports Q1 2024 Results, Corporate Update
13 May 2024 //
PR NEWSWIRE
Moleculin US Patent For Annamycin Lipid Delivery Tech
09 May 2024 //
PR NEWSWIRE
Moleculin Higher AML CR Rates, Durability In Interim Data
07 May 2024 //
PR NEWSWIRE
EMA Grants Orphan Drug Designation To Moleculin`s AML Treatment
18 Apr 2024 //
PR NEWSWIRE
Moleculin Presents Positive Annamycin Data
10 Apr 2024 //
PR NEWSWIRE
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
28 Mar 2024 //
PR NEWSWIRE
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting
27 Mar 2024 //
PR NEWSWIRE
Moleculin to Participate in the Virtual Investor Lunch Break
27 Mar 2024 //
PR NEWSWIRE
Moleculin to Present at the 36th Annual ROTH Conference
12 Mar 2024 //
PR NEWSWIRE
Moleculin Announces 2023 Year-End Annamycin Trials Data and 2024 Expectations
24 Jan 2024 //
PR NEWSWIRE
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials
13 Nov 2023 //
PR NEWSWIRE
Moleculin Doses First Subjects in Phase 2 Portion of Trial Evaluating Annamycin
02 Oct 2023 //
PR NEWSWIRE
Moleculin Announces Positive Independent Report of No Cardiotoxicity
18 Sep 2023 //
PR NEWSWIRE
Moleculin to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
PR NEWSWIRE
Moleculin Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
PR NEWSWIRE
Moleculin Provides Update on Trials and Outlines Expected Upcoming Milestones
10 Aug 2023 //
PR NEWSWIRE
Moleculin to Participate in the Healthcare Conference Presented by Maxim Group
13 Jun 2023 //
PR NEWSWIRE
Moleculin Provides Update on Ongoing Trials & Outlines Expected Milestones
10 May 2023 //
PR NEWSWIRE
Moleculin to Report 1Q FYR on May 11, 2023 & Host Conference Call & Webcast
04 May 2023 //
PR NEWSWIRE
Moleculin Successfully Completes 1st Cohort Ph 1b/2 Trial Evaluating Annamycin
02 May 2023 //
PR NEWSWIRE
Moleculin Announces Interim Phase 2 Data in STS Clinical Trial
22 Mar 2023 //
PR NEWSWIRE
Moleculin Announces Acceptance of Abstract to be Presented at AACR
21 Mar 2023 //
PR NEWSWIRE
Moleculin Announces Dosing of First Subject for Phase 1/2 Evaluating Annamycin
01 Mar 2023 //
PR NEWSWIRE
Italy grants clearance for Moleculin’s Phase I/II leukaemia therapy trial
22 Dec 2022 //
CLINICALTRIALSARENA
Moleculin Reports 80% Response Rate in Final Cohort of PI Trial of Annamycin
15 Dec 2022 //
PRNEWSWIRE
Moleculin Granted FDA Fast Track Designation of WP1122
07 Dec 2022 //
PRNEWSWIRE
Moleculin Reports Third Quarter 2022 FYR and Provides Pipeline Update
10 Nov 2022 //
PRNEWSWIRE
Moleculin Provides Update on Second MAD Cohort in Ph1a Trial of WP1122
14 Oct 2022 //
PRNEWSWIRE
WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies
27 Sep 2022 //
PRNEWSWIRE
Moleculin Biotech to Present at the Investor Innovations inAML) Event
23 Sep 2022 //
PRNEWSWIRE
Moleculin to Present at the H.C. Wainwright Global Investment Conference
07 Sep 2022 //
PRNEWSWIRE
Moleculin Receives FDA Orphan Drug Designation of WP1122
06 Sep 2022 //
PRNEWSWIRE
Moleculin Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
PRNEWSWIRE
Moleculin Concludes PIb and Opens Recruitment in PII Trial of Annamycin
28 Jul 2022 //
PRNEWSWIRE
Moleculin Announces Completion of Second SAD Cohort in PIa Trial of WP1122 in UK
08 Jul 2022 //
PRNEWSWIRE
Moleculin Completes First SAD Cohort in PIa Trial of WP1122 in UK
16 Jun 2022 //
PRNEWSWIRE
Moleculin initiates subject dosing in Phase Ia Covid-19 treatment trial
27 May 2022 //
CLINICALTRIALSARENA
